Skip to content
drillr.ai
Sign up

02315.HK

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

HKSE · Healthcare · Biotechnology · CN

HKD 38.30
−8.81%
Ask drillr

  • Oct 29, 2026, 08:21 UTC

    Biocytogen Pharmaceuticals (Beijing) Co., Ltd. reported year-to-date revenue of RMB 1.403 billion and net profit attributable to shareholders of RMB 312 million, up 49.09% and 173.77% year over year, respectively.

    Source:

  • Oct 29, 2026, 08:21 UTC

    Biocytogen Pharmaceuticals (Beijing) Co., Ltd. reported third-quarter 2026 revenue of RMB 461 million, up 44.22% year over year, and net profit attributable to shareholders of RMB 71.3552 million, up 7.91%.

    Source:

  • Sep 16, 2026, 09:53 UTC

    Biocytogen's board approved adjustments to its IPO fundraising project "Drug Early R&D Service Platform Construction Project", raising the total investment from 454 million yuan to 462 million yuan, with the additional 8 million yuan funded by its own funds while the raised funds invested remain unchanged at 454 million yuan, and changing the payment method for the remaining construction costs to a leasing model, with the project's expected usable date extended to June 30, 2027.

    Source:

  • Aug 27, 2026, 08:46 UTC

    Biocytogen Pharmaceuticals announced its interim results for the six months ended June 30, 2026, reporting net profit of 241 million RMB, up 402.3% year-on-year, and revenue of 941 million RMB, up 51.6% year-on-year.

    Source:

  • Aug 6, 2026, 15:40 UTC

    Biocytogen expects net profit attributable to parent for the first half of 2026 to be 236.0944 million to 246.0944 million yuan, up 391.87% to 412.71% year-on-year.

    Source:

  • Aug 5, 2026, 04:00 UTC

    Biocytogen-B (2315.HK) shares rose 9.7235% on August 5, 2026, becoming the top gainer among the Hong Kong Commercial Daily*HK Tech Index constituents that day.

    Source:

  • Jul 21, 2026, 19:36 UTC

    Several Chinese public funds, including E Fund, China Asset Management, Fullgoal Fund, and China Universal Fund, increased their holdings in Hong Kong-listed biotech stocks, triggering the 5% disclosure threshold for Baioct-B, 3SBio, CSPC Pharmaceutical Group, Kelun-Biotech, and H&H International Holdings.

    Source: